Pulmonary edema treatment
Reading File
Finding Sources
Searching PubMed
"pulmonary edema" AND treatment
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive content from Harrison's 22E and other sources. Let me compile the answer.
Pulmonary Edema: Treatment
Overview
Treatment depends on the specific etiology — cardiogenic (high-pressure) vs. noncardiogenic (increased permeability). As an acute, life-threatening condition, multiple measures must be applied simultaneously to support circulation, gas exchange, and lung mechanics. Complicating conditions — infection, acidemia, anemia, acute kidney dysfunction — must be corrected in parallel.
1. Support of Oxygenation and Ventilation
| Modality | Details |
|---|---|
| Oxygen therapy | Goal O₂ saturation ≥92%. High-flow nasal cannula (HFNC) preferred over BiPAP for non-cardiogenic shock acute hypoxemic respiratory failure with normal PaCO₂ |
| Noninvasive ventilation (NIV) | CPAP or BiPAP — rests respiratory muscles, improves oxygenation and cardiac function, reduces intubation need. Effective in cardiogenic pulmonary edema. Helmet ventilation is a newer technique |
| Mechanical ventilation with PEEP | Decreases preload and afterload; redistributes lung water from intraalveolar → extraalveolar space; increases lung volume to prevent atelectasis. Reserved for NIV failures |
| Sitting position | Legs dangling at bedside reduces venous return (preload) in non-hypotensive patients — simple but effective |
2. Reduction of Preload
Diuretics
- Furosemide (loop diuretic) is the agent of choice — acts as both a diuretic and a venodilator, reducing preload before diuresis begins
- Initial dose: ≤0.5 mg/kg IV; up to 1 mg/kg in renal insufficiency, chronic diuretic use, or hypervolemia
- Combination diuretics or continuous infusion for refractory cases
- Bumetanide and torsemide are alternatives
Nitrates
- Sublingual nitroglycerin 0.4 mg × 3 every 5 min — first-line for acute cardiogenic pulmonary edema
- If edema persists without hypotension → IV nitroglycerin at 5–10 μg/min (titrate up)
- IV nitroprusside 0.1–5 μg/kg/min — potent venous and arterial vasodilator; useful with hypertension; requires arterial line for BP monitoring; avoid in reduced coronary perfusion states
Morphine
- 2–4 mg IV boluses — transient venodilation + anxiolysis, reduces catecholamines and tachycardia
- ⚠️ Registry data shows increased mortality with morphine use; use with caution
ACE Inhibitors
- Reduce both preload and afterload; recommended for hypertensive patients
- In acute MI with heart failure → reduce short- and long-term mortality
Nesiritide (IV recombinant BNP)
- Potent arterial and venous vasodilator with diuretic properties
- Reserved for refractory cases; avoid in ischemia or acute MI
3. Inotropic and Vasopressor Support
Used when pulmonary edema is accompanied by reduced cardiac output or cardiogenic shock:
| Agent | Mechanism | Notes |
|---|---|---|
| Dobutamine | β₁ agonist → ↑ contractility | First-line inotrope in cardiogenic shock |
| Dopamine | Dose-dependent: inotrope + vasopressor | Used at medium–high doses |
| Milrinone (PDE-3 inhibitor) | Inotrope + peripheral/pulmonary vasodilation | 50 μg/kg load → 0.25–0.75 μg/kg/min; useful for severe LV dysfunction |
| Angiotensin II | Vasoconstrictor, possible positive inotrope | Expensive; no proven additive benefit over other vasopressors |
| Digitalis glycosides | Rate control in atrial arrhythmias | Rarely used as primary inotrope now |
4. Renal Replacement Therapy
Indicated for refractory volume overload with:
- Metabolic acidosis (pH <7.15–7.25)
- Persistent hypoxemia
- Refractory hyperkalemia
- Continuous RRT (CRRT) preferred over intermittent hemodialysis in hemodynamically unstable patients
For CKD patients specifically — arrange dialysis urgently as it is the most effective means of volume removal when renal function is absent.
5. Treat Underlying Cause
| Etiology | Specific Treatment |
|---|---|
| Acute MI (ST-elevation) | Immediate coronary revascularization (PCI/thrombolysis) |
| Arrhythmia | Rate/rhythm control |
| Hypertensive emergency | IV antihypertensives (nitroprusside, nitroglycerin) |
| Noncardiogenic (ARDS) | Lung-protective ventilation (low tidal volume), treat underlying sepsis/pneumonia/aspiration |
| CKD/ESRD | Urgent dialysis; sublingual nitroglycerin as bridge |
6. Monitoring
- Pulmonary artery catheter (PAC): measures PCWP — differentiates cardiogenic (elevated PCWP) from noncardiogenic (normal PCWP). Indicated when etiology is uncertain or edema is refractory
- BNP/NT-proBNP: substantially elevated levels support cardiogenic etiology
- Echocardiography: identifies LV/RV dysfunction, valvular pathology
- ECG: ST elevation → prompt MI protocol
Key Distinctions
| Feature | Cardiogenic | Noncardiogenic (ARDS) |
|---|---|---|
| PCWP | Elevated (>18 mmHg) | Normal |
| Protein content of edema fluid | Low | High |
| Resolution | Often rapid with treatment | Slow (days–weeks) |
| Primary treatment | Diuretics, vasodilators, inotropes | Lung-protective ventilation |
Sources: Harrison's Principles of Internal Medicine 22E (2025), Murray & Nadel's Textbook of Respiratory Medicine, Rosen's Emergency Medicine
This is a shared conversation. Sign in to Orris to start your own chat.